{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:42:54Z","timestamp":1695973374030},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>This study assessed treatment responses and economic consequences of limiting access to the second-generation BCR-ABL1 tyrosine kinase inhibitors (2G-TKI), dasatinib and nilotinib, for treatment of chronic myelogenous leukemia, while taking into account frequencies of genetic mutations that exhibit different sensitivities to the 2G-TKIs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Frequencies of <jats:italic toggle=\"yes\">BCR-ABL1<\/jats:italic> mutations and the impact of mutations on responses to 2G-TKIs were obtained from published literature and used as inputs in a decision analytics model. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were estimated after 12 months of 2G-TKI treatment. Total annual 2G-TKI drug costs per CHR and MCyR were estimated and compared among 3 2G-TKI access scenarios: (1) open access to both 2G-TKIs; (2) access restricted to dasatinib (DASA-only); and (3) access restricted to nilotinib (NILO-only).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among a hypothetical cohort of 1000 2G-TKI-treated chronic myelogenous leukemia patients, the percentage of patients with CHR and MCyR were greatest for the open access plan (CHR: 93%, MCyR: 56%), followed by DASA-only (88%, 53%) and NILO-only (67%, 47%). Compared with the 2G-TKI costs per CHR in open access ($120,706\/CHR), the costs were 5% higher ($126,753\/CHR) in DASA-only and 41% higher ($169,990\/CHR) in NILO-only. Likewise, compared with the 2G-TKI costs per MCyR in open access ($198,284\/MCyR), the costs were 6% higher ($209,259\/MCyR) in DASA-only and 22% higher ($241,515\/MCyR) in NILO-only.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Open access to both 2G-TKIs is associated with improved clinical and economic outcomes: greater treatment response rates (CHR and MCyR) and lower drug costs compared with restricted access to 2G-TKIs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000252","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T13:24:50Z","timestamp":1447853090000},"page":"213-217","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia"],"prefix":"10.1097","volume":"41","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinara","family":"Makenbaeva","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Lingohr-Smith","sequence":"additional","affiliation":[{"name":"Novosys Health, Green Brook, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Lin","sequence":"additional","affiliation":[{"name":"Novosys Health, Green Brook, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230928","first-page":"205","article-title":"Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia","volume":"3","author":"Ramchandren","year":"2009","journal-title":"Biologics"},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620714537865","article-title":"Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations","volume":"5","author":"Ai","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov Today Technol"},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3111\/13696998.2012.680555","article-title":"Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among a trial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials","volume":"15","author":"Deitelzweig","year":"2012","journal-title":"J Med Econ"},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1377\/hlthaff.2014.0001","article-title":"National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011","volume":"33","author":"Conti","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"R15-20230928","first-page":"32","article-title":"Oncologists plead for fairer drug payments","volume":"17","author":"Carroll","year":"2008","journal-title":"Manag Care"},{"key":"R16-20230928","first-page":"242","article-title":"Emerging trends in cancer care: health plans\u2019 and pharmacy benefit managers\u2019 perspectives on changing care models","volume":"5","author":"Greenapple","year":"2012","journal-title":"Am Health Drug Benefits"},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/14737167.2014.864561","article-title":"Trends in issues in oncology costs","volume":"14","author":"Scalo","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201803000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:11:50Z","timestamp":1695867110000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201803000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000252","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}